Last reviewed · How we verify
NCT04878952
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
NA trial testing Garmin Vivofit Activity Tracker in Non-small Cell Lung Cancer in 3 participants. Terminated before completion.
12 August 2024
Quick facts
| Lead sponsor | NRG Oncology |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 3 |
| Start date | 26 August 2021 |
| Primary completion | 12 August 2024 |
| Estimated completion | 12 August 2024 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- Garmin Vivofit Activity Tracker
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Non-small Cell Lung Cancer Stage III — all drugs for Non-small Cell Lung Cancer Stage III →
- Recurrent Non Small Cell Lung Cancer — all drugs for Recurrent Non Small Cell Lung Cancer →
Sponsor
NRG Oncology — full company profile →
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer or Non-small Cell Lung Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial will examine if the monitoring of daily step counts during a course of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer will enable clinicians to deliver improved supportive care and reduce the rate of adverse events during the course of radiation treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pilot Study of a Wearable Activity Monitor During Head and Neck Radiotherapy to Predict Clinical Outcomes.
Sher DJ, Radpour S, Shah JL, Pham NL, et al · · 2022 · cited 8× · PMID 35333597 · DOI 10.1200/cci.21.00179
Verify or expand the search:
- PubMed search for NCT04878952
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other NRG Oncology trials
Trials by the same sponsor.
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07452458 — Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, ID · Phase 3 · not yet recruiting
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07097142 — Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemothera · Phase 3 · recruiting
- NCT06958328 — Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04878952 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NRG Oncology
- Last refreshed: 4 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04878952.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing